![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
针对复发/耐药多发性髓瘤的BCMA向CAR-T治疗中长期结果的关键预测因素
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, P. R. China.
Journal of translational medicine
|May 16, 2025
概括
化学抗原受体T细胞 (CAR-T) 疗法在复发性/耐药性多发性髓瘤中显示出持久的反应. 持续的最小残留疾病负面性和CAR-T细胞持久性是长期疗效和改善生存的关键因素.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 针对B细胞成熟抗原 (BCMA) 导向的化学抗原受体T细胞 (CAR-T) 疗法在复发性/耐药性多发性骨髓瘤 (r/r MM) 中显示出高响应率.
- 在r/rMM中影响对BCMA CAR-T治疗反应持续时间的因素仍然不完全理解.
研究的目的:
- 分析 BCMA CAR-T 治疗在患有 r/r MM 的患者中的应答率和长期临床结果.
- 确定与BCMA CAR-T疗法的长期疗效相关的关键因素.
主要方法:
- 追溯观察性研究56名患者的r/rMM治疗equecabtagene自流细胞BCMACAR-T疗法.
- 分析整体应答率 (ORR),最小残留疾病 (MRD) 的消极性,完全应答 (CR),无进展生存 (PFS) 和整体生存 (OS).
主要成果:
- 观察到高ORR (96.4%) 和MRD负面性 (96.4%).
- 卡-T细胞持久性 (≥6个月) 和持续的MRD阴性与更好的结果和更长的PFS相关.
- 长时间的MRD消极性 (12-36个月) 与显著更长的PFS相关 (58个月到未达到).
结论:
- BCMA CAR-T 疗法可以在 r/r MM 患者的一个子集中诱导持久反应.
- 早期实现和维持MRD负面性对于改善长期预后和整体治疗结果至关重要.
更多相关视频
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
11.6K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
399
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:21Cancer Survival Analysis
313
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
313